AbbVie Advances Early-Stage ABBV-722 Tablet Study, Underscoring Pipeline Momentum

Abbvie (ABBV) announced an update on their ongoing clinical study.

Study Overview: AbbVie is running an early-stage trial called “A Phase 1 Study to Evaluate the Pharmacokinetics of a Tablet Formulation of ABBV-722 and the Effect of Food on Its Bioavailability in Healthy Adult Subjects.” The study tests how a new tablet version of ABBV-722 behaves in the body and how food changes its absorption. This work is important because it helps AbbVie design dosing instructions and decide how to move ABBV-722 forward in its pipeline, which can shape future revenue potential if the drug advances.

Intervention/Treatment: The only treatment in this study is ABBV-722, given as an oral tablet. Healthy adults receive single doses of the drug under different eating conditions. The goal is to understand how quickly and how much of ABBV-722 enters the bloodstream, and to see whether patients in the real world may need to take it with or without food.

Study Design: This is an interventional Phase 1 study in healthy volunteers. Participants are not randomly assigned; instead, they move through study periods in a set order (sequential design). Everyone knows what is being given and when, as there is no masking or placebo. The main aim is treatment-focused: to understand how the body processes ABBV-722 so future patient trials can use the safest and most effective dose schedule.

Study Timeline: The trial was first submitted on January 15, 2026, marking its formal entry into the clinical pipeline. As of the last update on January 23, 2026, the status is “recruiting,” meaning enrollment is underway. Primary completion and final completion dates are not yet listed, which is typical at this early stage, but investors should assume data readouts will come in phases over the next several quarters.

Market Implications: For AbbVie (ABBV), this update signals ongoing investment in new oral therapies and a steady flow of early pipeline projects. While single Phase 1 food-effect studies rarely move the stock on their own, they are key steps toward de-risking a candidate and sustaining the company’s longer-term growth story as it manages patent expiries in its core franchises. Positive progress here, combined with similar early-stage assets, can support sentiment that AbbVie’s pipeline is broad and active. In a competitive pharma landscape where peers like Pfizer, Merck, and Bristol Myers are also pushing oral drug programs, visible pipeline activity helps AbbVie defend its valuation premium and supports a narrative of durable innovation.

The study is ongoing and has been recently updated, with more details available on the ClinicalTrials portal.

To learn more about ABBV’s potential, visit the Abbvie drug pipeline page.